VOLY: The Monetary Value of a Life-Year at the End of Patients ’ Lives

ConclusionsThe pressure to reimburse expensive therapies targeting EoL conditions will continue to increase. Delivering “value for money” in healthcare, both in countries with relatively higher and lower budget restrictions, requires the valuation of different types of health gains, which should, in turn, affect our ability to evaluate their cost effectiveness.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research